![]() There is an urgent need of bringing these kind of therapies in the first line of management of functionally active neuroendocrine tumors.”ĭr. Despite advancement in traditional therapies, novel approaches and therapies are required to further increase patients’ overall survival and improve quality of life. ![]() Prasad noted, “The patient data gathered in the clinic under a compassionate use basis is not only remarkable but an extremely encouraging sign for Perspective Therapeutics’ VMT-α-NET program for the treatment of neuroendocrine tumors. The initial response was measured by a somatostatin imaging agent 6 8Ga-DOTANOC and demonstrated encouraging results after a single low dose of 212Pb-VMT-α-NET.ĭr.The result from first patient dosed with 212Pb-VMT-α-NET in India on a compassionate use basis showed favorable responses after the first dose.Highlights of the presented results include: Dr Vikas Prasad presented the results at the 2023 PET Radiotracer T ranslation and Resource Center (PET-RTRC) Workshops & Scientific Session hosted by the Mallinckrodt Institute of Radiology (MIR) at Washington University in St. (formerly known as “Isoray, Inc.”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the presentation of extremely encouraging results regarding 212Pb-VMT-α-NET, its lead preclinical candidate for neuroendocrine tumors (NET), currently being used therapeutically in India on a compassionate use basis. 22, 2023 (GLOBE NEWSWIRE) - Perspective, Therap e utics, Inc.
0 Comments
Leave a Reply. |